BioSpace News Archive

ImmuneID, Inc. today announced that it has raised $50 million in Series A financing.

- Xenter Therapeutics Joins Xenter Hospital Technologies as New Business Unit to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health -

Antios Therapeutics, Inc. (“Antios”) today announced pharmacokinetic (PK), safety and efficacy data from a Phase 1b clinical trial of ATI-2173.

Growth in the global infrared and terahertz spectroscopy market can be influenced by technological advancements and strict regulations prevalent in the pharmaceutical sector.

A report published by Transparency Market Research sheds light on the key dynamics of the global market for bone densitometers and provides a basis to understand its competitive landscape.

Tiziana Life Sciences plc announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization, to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 and pulmonary inflammation.

Sosei Group Corporation announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study.

Alzheon, Inc. announced the publication of a peer-reviewed research paper, “Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression,” in the Special Issue Alzheimer’s Disease: Role and Structure of Soluble Oligomers of the International Journal of Molecular Sciences, available through open access at: https://doi.org/10.3390/ijms22126355.

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually.